Compare Johnson & Johnson (JNJ) vs Sea Limited (SE) Price & Performance

Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.

The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.

Sea Limited (SE) trades at $106.00, up 1.87% on the day, with a bearish technical signal despite bullish moving averages. The company reported strong revenue growth, with 2025 revenue reaching $22.94 billion and net income of $1.58 billion, though recent quarterly earnings have been mixed. Positive cash flow trends and a robust analyst consensus with a $131.00 price target highlight fundamental strength, but insider selling and competitive pressures present headwinds.

The outlook for SE is cautiously optimistic, driven by sustained revenue expansion and improving profitability. Key risks include execution challenges in its e-commerce and gaming segments, geopolitical tensions affecting operations, and insider selling activity. The stock's valuation multiples suggest growth expectations are priced in, requiring continued strong performance to justify further upside.